Effects of Temperature Control at Intravenous Oxaliplatin Administration Area on Venous Pain in Colorectal Cancer Patients
Keywords:venous pain, ; oxaliplatin, colorectal cancer, temperature control using a foil arm sleeve
Objective: To compare effects of temperature control at intravenous oxaliplatin administration area on colorectal cancer patients’ venous pain.
Design: Randomised control trial
Methodology: The subjects were 90 colorectal cancer patients treated with intravenous oxaliplatin at a super tertiary hospital. Using a computer-assisted technique, the subjects were equally divided into three groups of 30, each with an equal number of members of both sexes. The Control Group received standard care, each member covered with a poly-cotton blanket. For Experimental Group 1, local temperature-control was applied through foil arm sleeves. Experimental Group 2 received locally administered temperature-control through foil arm sleeves, together with pre-warmed medical solution dispensed by a fluid warmer set at 26 to 37 degrees Celsius. Data were collected between August and December 2019, through a demographic record form, the patients’ treatment records, and the Thai Short-form McGill Pain Questionnaire, and were analysed using Chi-square test and Kruskal-Wallis H.
Results: After receiving peripheral intravenous administration of oxaliplatin, Experimental Group 1 reported significantly lower median value of venous pain at 1.5 and 2 hours than the Control group did (p < .05), whilst Experimental Group 2’s median value did not differ from those of Experimental Group 1 and the Control group.
Recommendations: The results showed that using a foil arm sleeve as a sole temperature control tool was more effective in reducing venous pain than using both a foil arm sleeve and pre-warmed solution, and than using a poly-cotton blanket. Therefore, nurses should apply this method in order to prevent and reduce colorectal cancer patients’ venous pain during intravenous oxaliplatin administration.
American Cancer Society. Facts and figures. [internet]. 2020. [Retrieved May 7, 2020]. Retrived from
https://www.cancer.org/content/dam/cancer-org/ research/cancer-facts-and statistics/annual- cancerfacts-and-figures/2020/cancer-facts-and-figures-2020.pdf
Medical Record Division Siriraj Hospital. Colorectal cancer statisitcs. Mahidol University: Faculty of Medicine, Siriraj Hospital; 2019.
Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29(11):1465-71.
Lin B-R, Lin Y-L, Lai H-S, Lee P-H, Chang K-J, Liang J-T. Overall survival of stage III colon cancer with only one lymph node metastasis is independently predicted by preoperative carcinoembryonic antigen level and lymph node sampling status. J PLoS One 2015;10(9):e0137053-62.
Matsuyama K, Mishima H, Ueno H, Kajihara K, Morioka A, Morimoto S, et al. Etiology and management
of venous pain during intravenous administration of oxaliplatin. Gan To Kagaku Ryoho 2011;38(3): 411-4.
Takagi A, Yonemoto N, Aoyama Y, Touma Y, Kajiwara M, Watanabe K, et al. Search for factors
related to vascular pain expression upon administration of oxaliplatin into a peripheral vein. Gan To Kagaku
Suga Y, Ikeda N, Maeda M, Staub AY, Shimada T, Yonezawa M, et al. Risk factors for oxaliplatin-induced
vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods. J
Pharm Health Care Sci 2018;4(1):18.
Kawazoe H, Sumikawa S, Nakauchi K, Yakushijin Y, Yamamoto Y, Watanabe Y, et al. Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain. Int J Clin Pharm 2017;39(6):1291-7.
Attal N, Bouhassira D, Gautron M, Vaillant J, Mitry E, Lepere C, et al. Thermal hyperalgesia as a marker
of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 2009;144(3):245-52.
Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti
P, Campagnolo M, Lonardi S. Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: results from a prospective multicenter
study. Cancer 2013;119(19):3570-7.
Park SB, Lin CS-Y, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009;132(10): 2712-23.
Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatininduced peripheral nerve damage. Cancer Treat Rev 2008;34(4):368-77.
Carozzi V, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 2015;596(1):90-107.
Habjaroen S, Werakul R. The effects of hot compresses with electric blankets on the peripheral neuralgia of
colorectal cancer patients receiving oxaliplatin. Thai Cancer Journal 2011; 31(2):41-53. (in Thai).
Miyajima R, Kawazoe H, Tsuneoka K, Fujiwara M, Kojima Y, Yakushijin Y. Preventive trial of preheating
administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced
venous pain. Gan To Kagaku Ryoho 2013;40(4): 537-40.
Nagao S, Furihata M, Fukagawa K, Furihata T, Matsuhashi Y, Wada T. Premedication with fast-acting
oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. J Infect
Cathomas R, Koberle D, Ruhstaller T, Mayer G, Rass A, Mey U, et al. Heated (37° C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 2010;18(10):1263-70.
Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359-67.
Applied Innovation Centre: AI Centre Mahanakorn University of Technology. [internet]. 2011. [Retrieved
January 29, 2019]. Retrived from https://www.dek-d.com/board/view/2346770/
Grothey A, editor Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;4(15):5-13.
Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;10(12): 4055-61.
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91.
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. Statistical power analyses using G*Power 3.1: tests
for correlation and regression analyses. Behav Res Methods 2009; 41(4):1149-60.
Pitisutthitham P, Pichiansunthorn C. Textbook of clinical research. Bangkok: Vaccine Center, Mahidol University, Faculty of Tropical Medicine; 2018. 660 p. (in Thai).
Kitisomprayoonkul W, Klaphajone J, Kovindha A. Thai Short-form McGill Pain Questionnaire. J Med
Assoc Thai 2006;89(6):846-53.
Bijur, P. E., Silver, W., & Gallagher, E. J. Reliability of the visual analog scale for measurement of acute
pain. Acad Emerg Med 2001;8(12):1153–7.
Yoshida, Y., Hoshino, S., Aisu, N., Shiwaku, H., Beppu, R., Tanimura, S., & Yamashita, Y. Dexamethasone as
a means for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein and
also for controlling oxaliplatin-induced hypersensitivity reactions. J Clin Oncol 2012;30(4): 662-2.
Lautenbacher S, Peters JH, Heesen M, Scheel J, Kunz M. Age changes in pain perception: A systematic-review
and meta-analysis of age effects on pain and tolerance thresholds. Neurosci Biobehav Rev 2017; 75:104-13